We are seeking pilot projects and strategic partners!
We specialize in central coordination of follow up eVisits to an array of trial participants. Whether your trial involves daily log entries or monthly follow up visits, our bring your own device (BYOD) for remote visits reduces travel burden for your participants as they replace up to 80% of their physical brick and mortar site visits with eVisits.
We understand technology is means to an end. We strive to achieve the right balance between use of technology and expert human intervention to optimize trial operations including the use of AI to recommend real time adjustments to an ongoing trial based on lessons learned from past clinical trials data.
Companionship is key to a trusted relationship with our caregivers. We not only strive to help you with everyday tasks but want to develop a caring relationship with you. We provide one-on-one attention and care that cannot compare in other settings.
Our founder's inspiring story and purpose that drives us. Listen to our Founder and CEO, Harsha Rajasimha, PhD present his vision and mission.
Longitudinal cohort studies aim to conveniently collect clinical, behavioral, lifestyle and environmental data from participants in real-world over extended periods of time. Our BYOD (bring your own device) offering to study investigators simplifies onboarding, engagement and retention of participants
Cell and gene therapy trials typically involve one time therapy administration upfront with long-term follow up with patients for safety monitoring.
Physical site visit requirements over a long period of time places undue burden on trial participants. Jeeva simplifies this process by fitting the trial into the patients lifestyle.
Our experienced and highly trained coordinators provide the highest quality of video-conferencing visits for patients and caregivers. Our goal is to help simplify and manage the trial operations to minimize burden, reduce drop outs, improve compliance and accelerate therapy development.
"No one knows the long term implications of cell and gene therapies because they are a one and done type treatment. If a patient receives therapy today, they are done, and so the FDA has mandated that recipients need to be monitored for up to 15 years. We are looking to address this issue with digital health technologies and AI,” says Harsha Rajasimha, Founder and CEO of Jeeva.
"We are excited to support Jeeva in their mission to decentralize clinical research, reduce patients' travel burden and optimize operations. Though Jeeva set out on their vision much before the current pandemic, it has become particularly relevant in the context of COVID-19. We look forward to helping Jeeva further its mission and scale through our unique startup ecosystem." said Rakesh Gupta, Co-Founder, and CEO of KiwiTech.
#CITGapFunds #CIT #Investor #Decentralized #ClinicalTrials
Harsha Rajasimha teamed up with the Mason SBDC and the SBDC’s Innovation Commercialization Assistance Program (ICAP). ICAP director Bob Smith helped Harsha take his concept to the next level. After successfully interviewing 146 customers in seven weeks, Jeeva rose to the top of the ICAP leaderboard and was accepted into the Spring 2019 cohort of the National Science Foundation (NSF) I-Corps program.
Listen to this featured interview of Jeeva Founder and CEO Harsha Rajasimha with rare disease PODCAST host Ilana Bean of Patient Worthy. Our founder shares his inspiring journey and the life changing trigger that lead him to set out on this mission to reduce the burden on both patients and research teams by 50% to 80% to accelerate the development of life-saving therapies.The podcast was recorded at National Institute of Health at Bethesda, MD on the sidelines of RareDiseaseDay 2020.
Jeeva will be exhibiting and presenting Jeeva decentralized clinical trials technology platform at the Expanded Access Summit 2020 at the National Press Club, Washington DC Jan 27 - 29, 2020. Clinical Investigators and Operations Professionals can schedule a free consultation or product demo using the online appointment booking system on our website.
Founder and CEO of Jeeva Informatics will be pitching to silicon valley investors and networking at cocktail receptions including VABIO, Cooley, Indiebio and WSGR. The first VC-backed company to bring decentralized clinical trials technology for cell/gene therapy market. #longtermfollowups #ltfu
"AI and Bigdata strategies in accelerating clinical research for faster rare disease cures." - Keynote presentation by our Founder & CEO, Dr. Harsha Rajasimha at the BioIT World West Conference. Harsha will also be a panelist to share multi-stakeholder perspectives.
Jeeva will be at the Pharma Forum looking for meaningful investor, customer and strategic partnership conversations at the HIMSS20 Global Health Conference and Exhibition. Schedule your appointment with our CEO!
“In my twenty years of experience in clinical trials, every trial has seemed like the first-ever trial undertaken by mankind. Jeeva offers a fresh perspective on optimizing virtual clinical trials operations. I think cell and gene therapy trials will particularly benefit from Jeeva's solution. Hence, I am investing in and supporting this nimble startup!"
“As a global patients advocacy organization, we can say with authority that mobility and travel issues are serious bottlenecks for clinical trials participation. A home health care based simple solution to this problem is sure to have a huge impact on the rare diseases patients community globally!”
“Cell and gene therapy technologies promise cures for genetic diseases. Jeeva's solution is unique and solves an unmet need to simplify small population clinical trials. That's why I have invested in the company."
Enabling precision medicine cohort studies at the community level
You can book an appointment with our Founder and CEO above. Or submit this form with your questions. We will get back to you as soon as we can.
8000 Towers Crescent Dr, Suite 1110, Vienna, VA 22182
09:00 am – 07:00 pm
English speaking countries